| Business Summary | | Electropharmacology,
Inc.
previously
created
novel
products
for
the
improved
treatment
of
complex
human
diseases
such
as
cancer,
wounds,
chronic
infections,
inflammation
and
tissue
degeneration
associated
with
aging
or
autoimmune
disorders.
The
Company's
primary
focus
was
on
products
for
diseases
that
affect
superficial
tissues
such
as
skin,
breasts,
brain,
prostate
and
joints.
On
March
23,
2001,
the
Company
announced
that
due
to
the
cancellation
of
the
license
with
Elan
Corporation
and
its
subsidiaries'
inability
to
satisfy
past
operating
debt,
service
long-term
debt,
fund
current
and
future
operating
expenses,
the
Company
suspended
operations,
laid
off
most
of
the
its
staff,
and
began
to
explore
options
to
sell
its
assets. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | EPHI
suspended
operations
and
is
exploring
the
sale
of
its
assets.
EPHI
developed,
manufactured
and
marketed
medical
devices
that
deliver
pulsed
electromagnetic
signals
in
the
radio
frequency
range.
For
the
fiscal
year
ended
12/31/00,
revenues
fell
23%
to
$396
thousand.
Net
loss
applicable
to
common
fell
21%
to
$2.3
million.
Revenues
suffered
from
decreased
product
sales
and
the
relocation
of
the
Gemini
operations.
Net
loss
reflects
a
decreased
loss
on
the
sale
of
securities. | More
from
Market Guide: Significant
Developments |
| Officers | | | FY1999 Pay | |
| Arup Sen, Ph.D., 48 Chairman,
Pres, CEO, Chief Financial Officer, Sec. | $331K | Richard Kneipper, 56 Vice
Chairman | -- | Dollar amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|